Harry Cassin
Publisher and Editor
Andy Spalding
Senior Editor
Jessica Tillipman
Senior Editor
Bill Steinman
Senior Editor
Richard L. Cassin
Editor at Large
Elizabeth K. Spahn
Editor Emeritus
Cody Worthington
Contributing Editor
Julie DiMauro
Contributing Editor
Thomas Fox
Contributing Editor
Marc Alain Bohn
Contributing Editor
Bill Waite
Contributing Editor
Russell A. Stamets
Contributing Editor
Richard Bistrong
Contributing Editor
Eric Carlson
Contributing Editor
At the Cambridge Symposium on Economic Crime at Jesus College Tuesday, David Green QC, the head of the UK Serious Fraud Office, described what he called a cross section of the SFO’s current caseload.… Continue Reading
Chinese regulators are stepping up anti-corruption enforcement, putting Western and local executives and the companies they work for at greater risk. So it’s important to know which laws in China are most relevant and what preventive action should be taken in response to the increased enforcement.
The photo released by the Shanghai court shows Peter Humphrey (left) and his wife Yu Yingzeng (in red)The British investigator who once worked for GlaxoSmithKline was sentenced to two-and-a-half years in jail for trafficking personal data in China.… Continue Reading
In Part 1 of this series, the author probed the assertion by many companies they have “zero tolerance for unethical or illegal behavior.”
In Part 2 he asks why, if most large businesses have fraud, risk and corruption-related policies in place, are there still so many cases of fraud and corruption?… Continue Reading
A recent post on FCPA Blog about various ongoing investigations into alleged corrupt practices at GlaxoSmithKline in at least five countries included a quote attributed to GSK that the company has “zero tolerance for unethical or illegal behavior.”
In-house lawyers, we said yesterday, are now caught between their duty as advocates on the one hand, and the modern concept of ethics and compliance on the other hand. Talk about a headache.… Continue Reading
Press reports that GlaxoSmithKline fired employees of its China unit in 2001 for paying bribes to government officials could complicate the company’s defense of current allegations about illegal sales practices in several countries.… Continue Reading
Prosecutors in China have filed formal charges against British private investigator Peter Humphrey and his American wife, the state-controlled Xinhua news agency said Monday.
Humphrey and Yu Yingzeng, his wife and business partner, were arrested a year ago.… Continue Reading
The trial of a British corporate investigator and his American wife who once worked with GlaxoSmithKline will be closed to the public and foreign consular officials, the South China Morning Post reported Thursday.… Continue Reading
GlaxoSmith Kline PLC is under investigation by the UK Serious Fraud Office for possible criminal violations, the pharma said Tuesday.
In a two-sentence statement, UK-based GSK said it had been informed by the SFO of a formal criminal investigation into GSK’s commercial practices.… Continue Reading
Chinese police Wednesday charged the British former boss of GlaxoSmithKline’s China unit and two other company executives with corruption for bribing health officials and doctors.
A Ministry of Public Security official said in Beijing that Mark Reilly (pictured) and two Chinese executives, Zhang Guowei and Zhao Hongyan, offered bribes to hospital personnel and doctors to boost GSK’s sales.… Continue Reading
GlaxoSmithKline said it is investigating allegations of bribery in Jordan and Lebanon first reported by the media.
The UK-based pharma giant said in a statement Wednesday the probes are ongoing.
GSK said it has a “zero tolerance” for illegal behavior.… Continue Reading
